Hemab Therapeutics Pulls Back After 53% IPO Surge
Hemab Therapeutics (COAG) will open Wednesday pre-market at $27.47, up 53% from its $18 IPO price. The company raised $346.7 million in its May IPO, ending March with $163.5 million in cash before IPO proceeds. Hemab plans a pivotal Phase 3 trial for its lead drug, sutacimig, in Glanzmann thrombasthenia in late 2026. CEO Benny Sørensen said data from key programs is expected by late 2026 or early 2027.